MRNA · Moderna, Inc.

conf –

enthusiasm:15.0 · trend:8 · quantifies:0 · impact:0 · under_radar:0 · credibility:0 · business_impact:4 · disruption:0 · commitment:-4 · confirmation:3

Enthusiasm latest 5 / prev 4 (rising)

Across both calls, AI is framed narrowly as an internal productivity and cost-discipline lever—not as a revenue driver, product feature, or quantified margin/headcount outcome. Management moved from claiming broad adoption (Q4 FY2025) to pledging continued investment, cross-enterprise “reinvent work” projects, and a Science Day preview of AI plus robotics for discovery (Q1 FY2026), but offered no numbers, no analyst Q&A, and no proof of attributable business impact. Credibility is low for an investable AI thesis until Science Day or future calls tie AI to measurable cost, R&D cycle time, or pipeline outcomes.

• Q4 FY2025 — Stéphane Bancel: As part of our cost efficiency program, the adoption of AI tools has touched every part of our business, and we expect further productivity improvement in 2026.

• Q1 FY2026 — Stéphane Bancel: We'll continue to invest in AI with a number of cross enterprise projects to reinvent work with AI.
• Q1 FY2026 — Stéphane Bancel: We will, of course, continue to drive increased personnel productivity across the company.

• Q4 FY2025 — Stéphane Bancel: …we expect further productivity improvement in 2026.
• Q1 FY2026 — Stéphane Bancel: …Science Day on June 25… also how we're using AI and robotics to accelerate our ability to discover new technology to expand the use of mRNA to new drug modalities.

—/100 (no quantified promises)   no-quantified-promises  6 calls reviewed

Across six calls Moderna cites AI, digital tools, and GPTs as contributors to broad cost and productivity programs but never sets a numbered, dated AI target (e.g., % savings or headcount from AI by year-end). Without quantified AI commitments there is no promise-versus-delivery track record to score.

Est. revisions rising  ·  Fwd P/E -5.8  ·  EV/Sales 7.9x

AI claim maps to Product Sales

AI enthusiasm across 6 calls — trend ↘ falling

Sparse ops-efficiency AI talk; CEO cited many GPTs in Q3 2025, then silence on later calls.

• 2026-05-12 · Moderna's AI Could Get a Hantavirus Vaccine Here Faster
• 2026-05-01 · Breakfast News: Atlassian Pops 25% On AI Power

5/10 qualitative impact   moderate  medium-term · soft evidence

Where AI matters: R&D discovery and internal cost productivity

Management ties AI to cost discipline and cross-enterprise productivity with no attributable savings or pipeline metrics, while forward discovery/robotics claims await Science Day proof.

Caveats: Unquantified AI productivity leaves upside unverifiable until Science Day or disclosed cycle-time/cost data; Peer adoption of generative discovery could narrow early-stage speed advantages without shifting late-stage moats; Cost-efficiency narrative may mask limited near-term margin impact from generic enterprise tooling

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

Revenue rests on approved biologics, clinical/regulatory barriers, and manufacturing scale—not billable labor or easily automated content—so AI mainly aids rather than replaces the core mRNA product model.

option liquidity: good

proxy inputs — dollar-ADV $332M · beta 1.056 · px $45.64

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.